Drugs Targeting NLRP3 Inflammasome in the Treatment of Diabetic Bone Disorders.

Yuyang Chen,Munire Aili,Fan Chen, Yu Gong, Xiaoju Chen,Lan Zhang

Endocrine, metabolic & immune disorders drug targets（2023）

引用 1|浏览3

暂无评分

摘要

The presented studies indicate that hyperglycemia is the initiating factor for NLRP3-induced bone disorders in diabetic patients. The main drug targets are the molecules relevant to the assembly and activation of NLRP3 inflammasome. These data may provide a theoretical basis for the further development of drugs targeting NLRP3 inflammasome in the treatment of diabetic bone disorders.

查看译文

关键词

Diabetes mellitus,NLRP3 inflammasome,bone disorders,diabetic complications,inflammatory response,new drug development,targeted drugs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要